GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD The second dose of Shingrix (recombinant zoster vaccine) may cause side effects that are worse than the first. The second dose is ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Some studies have also identified potential associations with dementia. The $1.7 million study, funded by GlaxoSmithKline (GSK), which makes Shingrix, will allow Harris to emulate two target trials ...

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...